Bacillus (e.g., B. Subtilis, B. Thuringiensis, Etc.) Patents (Class 435/252.31)
-
Publication number: 20150044215Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.Type: ApplicationFiled: March 4, 2013Publication date: February 12, 2015Applicant: Ablynx N.V.Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
-
Publication number: 20150044754Abstract: Provided are isolated polypeptides having alpha-amylase activity, catalytic domains, carbohydrate binding domains and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding domains. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding domains.Type: ApplicationFiled: September 7, 2012Publication date: February 12, 2015Inventors: Tianqi Sun, Ming Li, Junxin Duan
-
Publication number: 20150045290Abstract: Biosurfactants produced by a strain of Bacillus sp and to uses thereof. A composition comprising the biosurfactants, and a method for producing the biosurfactants. A method for obtaining a biosurfactant, and a device for implementing the method. The production of biopesticides or biosurfactants for the phytosanitary industry, and in the fields of the food, cosmetics, pharmaceutical and oil industries and the environment.Type: ApplicationFiled: October 3, 2012Publication date: February 12, 2015Applicant: Universite Lille 1-Sciences ET Technologies-USTLInventors: Francois Coutte, Philippe Jacques, Didier Lecouturier, Jean-Sebastien Guez, Pascal Dhulster, Valerie Leclere, Max Bechet
-
Publication number: 20150044747Abstract: The invention relates, in part, to nucleic acid constructs, genetically modified host cells and methods employing such constructs and host cells to increase the production of 3-methyl-2-butenol from IPP. Thus, in some aspects, the invention provides a genetically modified host cell transformed with a nucleic acid construct encoding a fusion protein comprising a phosphatase capable of catalyzing the dephosphorylation of dimethylallyl diphosphate (DMAPP) linked to an IPP isomerase capable of converting IPP to DMAPP, wherein the nucleic acid construct is operably linked to a promoter. In some embodiments, the genetically modified host cell 5 further comprises a nucleic acid encoding a reductase that is capable of converting 3-methyl-2-butenol to 3-methyl-butanol. In some embodiments, the reductase is encoded by a nucleic acid construct introduced into the cell. In some embodiments, the IPP isomerase is a Type I isomerase. In some embodiments, the IPP isomerase is a Type II isomerase.Type: ApplicationFiled: September 13, 2012Publication date: February 12, 2015Applicant: The Regents of the University of CaliforniaInventors: Howard Chou, Jay D. Keasling
-
Patent number: 8951937Abstract: A group of bacterial dihydroxy-acid dehydratases having a [2Fe-2S] cluster was discovered. Bacterial [2Fe-2S] DHADs were expressed as heterologous proteins in bacteria and yeast cells, providing DHAD activity for conversion of 2,3-dihydroxyisovalerate to ?-ketoisovalerate or 2,3-dihydroxymethylvalerate to ?-ketomethylvalerate. Isobutanol and other compounds may be synthesized in pathways that include bacterial [2Fe-2S] DHAD activity.Type: GrantFiled: March 15, 2013Date of Patent: February 10, 2015Assignee: Butamax Advanced Biofuels LLCInventors: Dennis Flint, Steven Cary Rothman, Wonchul Suh, Jean-Francois Tomb, Rick W. Ye
-
Publication number: 20150037860Abstract: This document describes biochemical pathways for producing isoprene by forming two vinyl groups in a central precursor produced from isobutyryl-CoA, 3-methyl-2-oxopentanoate, or 4-methyl-2-oxopentanoate as well as recombinant hosts for producing isoprene.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Inventors: Adriana Leonora Botes, Alex Van Eck Conradie
-
Publication number: 20150038675Abstract: The purpose of the present invention is to provide: a peptide having an affinity for silicon nitride; a polynucleotide encoding the peptide; an expression vector for expressing the peptide having an affinity for silicon nitride; an expression vector for expressing a peptide fusion protein that comprises the peptide having an affinity for silicon nitride and a target protein; a transformant obtained by introducing the expression vector into a host cell; a peptide fusion protein obtained from the transformant; a silicon nitride substrate to which a peptide having an affinity for silicon nitride has been bonded; a method for immobilizing a target protein to a silicon nitride substrate; a composition for immobilizing a target protein to a silicon nitride substrate, the composition comprising a peptide having an affinity for silicon nitride; and a linker for immobilizing a target protein to a silicon nitride substrate, the linker comprising a peptide having an affinity for silicon nitride.Type: ApplicationFiled: February 12, 2013Publication date: February 5, 2015Inventors: Yoichi Kumada, Michimasa Kishimoto, Takeru Otsuka
-
Publication number: 20150037872Abstract: The present invention relates to a method of selecting a protein variant having modified immunogenicity as compared to the parent protein comprising the steps obtaining antibody binding peptide sequences, using the sequences to localise epitope sequences on the 3-dimensional structure of parent protein, defining an epitope area including amino acids situated within 5 ? from the epitope amino acids constituting the epitope sequence, changing one or more of the amino acids defining the epitope area of the parent protein by genetical engineering mutations of a DNA sequence encoding the parent protein, introducing the mutated DNA sequence into a suitable host, culturing said host and expressing the protein variant, and evaluating the immunogenicity of the protein variant using the parent protein as reference. The invention further relates to the protein variant and use thereof, as well as to a method for producing said protein variant.Type: ApplicationFiled: October 15, 2014Publication date: February 5, 2015Inventors: Erwin Ludo Roggen, Steffen Ernst, Allan Svendsen, Esben Peter Friis, Claus Von Der Osten
-
Publication number: 20150038401Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Applicant: SYNTAXIN LIMITEDInventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
-
Publication number: 20150037845Abstract: The present disclosure relates to mutant thermostable glycosyl hydrolases family 7 enzymes, including mutant Trichoderma reesei endoglucanase I. In particular, the present disclosure relates to mutant thermostable enzymes, compositions containing the enzymes, and methods of use thereof.Type: ApplicationFiled: August 11, 2011Publication date: February 5, 2015Applicant: The Regents of the University of CaliforniaInventors: Harshal Akshay Chokhawala, Tae-Wan Kim, Harvey W. Blanch, Douglas S. Clark
-
Publication number: 20150037349Abstract: The present invention relates to polypeptides comprising one or more antibody single domains, or antigen-binding fragments thereof, directed against Tumor Necrosis Factor-alpha, in particular, two light chain variable domains in dimeric form, where the dimer has high solubility. It also relates to methods of using anti-Tumor Necrosis Factor-alpha polypeptides in treating inflammatory disorders, including rheumatoid arthritis. Compositions and methods for enhancing therapeutic potential of anti-Tumor Necrosis Factor-alpha polypeptides are provided, including linking the polypeptide to an albumin-binding domain and/or de-immunizing the polypeptide, to provide therapeutic agents with good solubility, enhanced serum half-life, and/or reduced immunogenicity, while substantially maintaining the specific binding properties of the anti-Tumor Necrosis Factor-alpha polypeptides.Type: ApplicationFiled: September 19, 2012Publication date: February 5, 2015Inventors: Frederico Nuno Castanheira Aires da Silva, Sofia Volker Côrte-Real, Rui Pedro da Silva Albuquerque e Freitas, Sara Ferreira Llorente Grancho Lourenço
-
Publication number: 20150040271Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Suchindra Maiyuran, Randall Kramer, Paul Harris
-
Publication number: 20150038673Abstract: The present invention relates to novel ?-AR homologous cyclopeptide-mutants comprising only two cysteine residues able to form an intramolecular linkage, to linear peptides that can form these cyclopeptide-mutants and to nucleic acid molecules encoding these cyclopeptide-mutants and linear peptides. Moreover, vectors and recombinant host cells comprising said nucleic acid molecule and a method for producing the disclosed cyclopeptide-mutants are provided. Further provided is a composition comprising the peptides, nucleic acid molecules, vectors or host cells of the invention. The present invention also relates to therapeutic and diagnostic means, methods and uses taking advantage of the peptides of the invention and to means, methods and uses for detecting anti-.beta.-adrenergic receptor antibodies like anti-?1-adrenergic receptor antibodies.Type: ApplicationFiled: August 5, 2014Publication date: February 5, 2015Inventors: Roland Jahns, Valerie Jahns, Martin Lohse, Viacheslav Nikolaev
-
Publication number: 20150030602Abstract: A novel monoclonal antibody and like antigen-binding molecules against transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFE2) are provided with unique immunological and biological properties useful in the therapy of affective disorders such as depression and bipolar disorders as well as anxiety disorders. In addition, pharmaceutical compositions and kits comprising such antibody and derivatives thereof are described.Type: ApplicationFiled: January 2, 2013Publication date: January 29, 2015Applicant: PHENOQUEST AGInventors: Ingeborg Sillaber, Marcelo Paez-Pereda
-
Publication number: 20150031082Abstract: The present invention relates to isolated polypeptides having beta-glucosidase activity, beta-xylosidase activity, or beta-glucosidase and beta-xylosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Inventor: Marc Dominique Morant
-
Publication number: 20150030584Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.Type: ApplicationFiled: August 5, 2014Publication date: January 29, 2015Applicant: SYNTAXIN LIMITEDInventor: Andreas Rummel
-
Publication number: 20150031109Abstract: The present invention provides compositions and methods for producing a polyol oxidase in micoroorganisms, and the use of polyol oxidases in cleaning compositions. The invention includes cleaning compositions that contain combinations of two or more POx oxidases, and cleaning compositions that contain combinations of two or more POx oxidases and a perhydrolase. In particular, the invention provides methods for expressing polyol oxidases in bacterial hosts for use in detergent applications for cleaning, bleaching and disinfecting.Type: ApplicationFiled: July 30, 2014Publication date: January 29, 2015Applicant: DANISCO US INC.Inventors: Manoj KUMAR, Susan M. MADRID, Hugh C. MCDONALD, Ayrookaran J. POULOSE, Thomas RAND, Huaming WANG
-
Publication number: 20150030625Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
-
Publication number: 20150031080Abstract: The present invention relates to variants of a parent cellobiohydrolase II. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Inventor: Mark Wogulis
-
Publication number: 20150031618Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homologue thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of ?1m.Type: ApplicationFiled: January 31, 2013Publication date: January 29, 2015Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
-
Publication number: 20150031079Abstract: The present invention relates to isolated polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Inventor: Nikolaj Spodsberg
-
Publication number: 20150031601Abstract: The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: August 11, 2014Publication date: January 29, 2015Applicant: ADDENIUM BIOTECH APSInventors: Hans-Henrik Kristensen Hoegenhaug, Per Holse Mygind, Thomas Kruse, Dorotea Raventos Segura, Dorthe Hoj Sandvang, Soren Neve
-
Patent number: 8940276Abstract: Provided are human alpha-synuclein-specific autoantibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for ?-synuclein are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: GrantFiled: December 21, 2009Date of Patent: January 27, 2015Assignees: Biogen Idec International Neuroscience GmbH, University of ZurichInventors: Andreas Weihofen, Jan Grimm, Roger Nitsch, Christoph Hock
-
Publication number: 20150024439Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: September 29, 2014Publication date: January 22, 2015Inventors: Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
-
Publication number: 20150025228Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20150024990Abstract: The present invention relates to novel subtilase variants exhibiting alterations relative to the parent subtilase in one or more properties including: Wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dishwash compositions, including automatic dishwash compositions.Type: ApplicationFiled: September 30, 2014Publication date: January 22, 2015Inventors: Tina Sejersgard Fano, Claus Von Der Osten, Malene Kappen Kruger, Mads Norregaard-Madsen
-
Publication number: 20150024450Abstract: One aspect of the invention relates to a genetically modified thermophilic or mesophilic microorganism, wherein a first native gene is partially, substantially, or completely deleted, silenced, inactivated, or down-regulated, which first native gene encodes a first native enzyme involved in the metabolic production of an organic acid or a salt thereof, thereby increasing the native ability of said thermophilic or mesophilic microorganism to produce ethanol as a fermentation product. In certain embodiments, the aforementioned microorganism further comprises a first non-native gene, which first non-native gene encodes a first non-native enzyme involved in the metabolic production of ethanol. Another aspect of the invention relates to a process for converting lignocellulosic biomass to ethanol, comprising contacting lignocellulosic biomass with a genetically modified thermophilic or mesophilic microorganism.Type: ApplicationFiled: May 7, 2013Publication date: January 22, 2015Applicant: Mascoma CorporationInventors: David Anthony Hogsett, Vineet Badriphrajad Rajgarhia
-
Publication number: 20150023958Abstract: A fusion polypeptide capable of binding simultaneously to angiopoietin 2, VEGF-C and VEGF-D; or capable of binding simultaneously to VEGF-C and VEGF-D, and methods for the preparation and use thereof.Type: ApplicationFiled: July 21, 2014Publication date: January 22, 2015Inventors: Kwang Hoon LEE, Hyung-Chan Kim, Sang Yeul Han, Seok Kyun Kim, Kyung Eun Kim
-
Publication number: 20150023966Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: November 6, 2012Publication date: January 22, 2015Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
-
Publication number: 20150026843Abstract: The present invention relates to isolated polypeptides having proteaseactivity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptidesin e.g. animal feed and detergents.Type: ApplicationFiled: December 20, 2012Publication date: January 22, 2015Inventors: Tine Hoff, Carsten Sjoeholm, Peter Rahbek Oestergaard, Katrine Pontoppidan
-
Publication number: 20150025227Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: ApplicationFiled: July 9, 2014Publication date: January 22, 2015Applicant: HANMI SCIENCE CO., LTD.Inventors: Sung Youb JUNG, Jin Sun Kim, Geun Hee Yang, Se Wang Kwon, Gwan Sun Lee
-
Publication number: 20150023889Abstract: Disclosed are compounds, compositions, and methods relating to fluoride aptamers, fluoride-responsive riboswitches, fluoride-regulated expression constructs, fluoride transporters, nucleic acids encoding fluoride transporters, expression constructs encoding fluoride transporters, and cells containing or including any combination of these.Type: ApplicationFiled: September 17, 2012Publication date: January 22, 2015Inventors: Ronald Breaker, Jenny Baker, Narasimhan Sudarsan, Zasha Weinberg, Adam Roth, Tyler Ames, James Nelson
-
Publication number: 20150024009Abstract: The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-CoA:sterol acyltransferase/sterol O-acyltransferase (EC 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol O-acyltranferase (EC 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (EC 2.3.1.158) and/or acyl CoA-wax alcohol acyltransferase (EC 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.Type: ApplicationFiled: September 19, 2014Publication date: January 22, 2015Applicant: ORGANOBALANCE GMBHInventors: Christine Lang, Andreas Raab
-
Publication number: 20150026840Abstract: To produce a bacterial microcompartment shell, or a designed shell based on naturally occurring bacterial microcompartment shells in a new host organism, a synthetic operon is constructed that contains the desired shell protein genes and translation efficiency is controlled by host specific ribosomal binding sites. Proteins or other molecules can be encapsulated in the microcompartment shells by various methods described herein. The constructs can also be used to express self-assembling sheets comprised of shell proteins.Type: ApplicationFiled: March 14, 2014Publication date: January 22, 2015Applicant: The Regents of the University of CaliforniaInventors: Cheryl A. Kerfeld, Jonathan K. Lassila, James N. Kinney
-
Publication number: 20150023995Abstract: The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.Type: ApplicationFiled: July 25, 2014Publication date: January 22, 2015Applicant: TAKEDA VACCINES, INC.Inventors: Charles RICHARDSON, Robert F. BARGATZE, Joel HAYNES, Bryan STEADMAN
-
Publication number: 20150017701Abstract: Hybrid alpha-amylases are provided that share a conserved 3D structure in whole or in part with a wild-type Termamyl-like ?-amylase, e.g., a Bacillus amylase. In the hybrid, an N-terminal portion of a Termamyl-like ?-amylase is replaced with sequences from an archae ?-amylase. The sequence similarity between the two amylase sequences may be less than 60%. Conserving the wild-type 3D structure in the hybrid facilitates obtaining enzymatically active amylases. In one embodiment, one or both amylase sequences contribute residues to the B domain, resulting in particularly advantageous properties. For instance, replacement of the Ca2+ binding site in the B domain of the Termamyl-like ?-amylase with a B domain sequence of an archae ?-amylase that does not bind Ca2+ can produce a hybrid that is fully active in the absence of Ca2+.Type: ApplicationFiled: July 25, 2014Publication date: January 15, 2015Applicant: DANISCO US INC.Inventors: Scott D. Power, Andrew Shaw
-
Publication number: 20150018522Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.Type: ApplicationFiled: March 10, 2014Publication date: January 15, 2015Applicant: The United States of America, as represented by the Secretary, Department of Health & Human ServicInventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
-
Publication number: 20150017696Abstract: The present disclosure relates to recombinant host cells comprising one or more recombinant polynucleotides encoding enzymes in select pathways that provide the ability to use the cells to produce 1,3-butadiene. The present disclosure also provides methods of manufacturing the recombinant host cells, and methods for the use of the cells to produce 1,3-butadiene, either through formation of the intermediate compound crotonol followed by chemo-catalytic dehydration to 1,3-butadiene, or through the use of a recombinant cell comprising a fully enzymatic pathway capable of converting crotonyl-CoA or crotonyl-ACP to crotonol and then crotonol to 1,3-butadiene.Type: ApplicationFiled: February 26, 2013Publication date: January 15, 2015Inventors: Simon Christopher Davis, Nicholas J. Agard, John H. Grate
-
Publication number: 20150017178Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.Type: ApplicationFiled: February 19, 2014Publication date: January 15, 2015Inventor: Antonio Francesco DI NARO
-
Publication number: 20150018229Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein. Also provided is an antibody to the polypeptide, a transgenic animal, and a solid support comprising one or a plurality of the provided polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also provided. In addition, the invention relates to methods for producing a pharmaceutical composition, diagnosing a disease and detection of the polynucleotide.Type: ApplicationFiled: May 13, 2014Publication date: January 15, 2015Inventors: Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
-
Publication number: 20150017698Abstract: The present disclosure relates to recombinant host cells comprising one or more recombinant polynucleotides encoding enzymes in select pathways that provide the ability to use the cells to produce 1,3-butadiene. The present disclosure also provides methods of manufacturing the recombinant host cells, and methods for the use of the cells to produce 1,3-butadiene. The methods utilize recombinant host cells that comprise an engineered pathway of enzymes that provides for the conversion of naturally occurring intermediate crotonyl-CoA (or -ACP) to 1,3-butadiene through enzyme catalyzed steps involving the reduction of glutaconyl-CoA (or -ACP) to form the intermediate 5-hydroxypent-3-enoate. The disclosure provides alternative engineered pathway involving either decarboxylation of 5-hydroxypent-3-enoate directly to 1,3-butadiene, or phosphorylation of 5-hydroxypent-3-enoate followed by a phosphate elimination step catalyzed by a decarboxylase to produce 1,3-butadiene.Type: ApplicationFiled: February 26, 2013Publication date: January 15, 2015Inventors: Gregory A. Cope, Louis Clark
-
Patent number: 8932841Abstract: A thermophilic microorganism is modified to permit the increased production of ethanol, wherein a first modification is the inactivation of the lactate dehydrogenase gene and a second modification upregulates the pyruvate dehydrogenase gene.Type: GrantFiled: September 28, 2007Date of Patent: January 13, 2015Assignee: TMO Renewables LimitedInventors: Anthony Atkinson, Roger Cripps, Brian Rudd, Kirstin Eley, Steve Martin, Paul Milner, Claire Mercier
-
Publication number: 20150010978Abstract: Terpene synthases are enzymes that directly convert IPP & DMAPP to terpenes, such as fusicoccadiene. Described herein are methods and compositions for the production of terpenes and terpenoids for use as fuel molecules or other useful components. Genetically engineered enzymes capable of producing terpenes and terpenoids are also described.Type: ApplicationFiled: August 28, 2014Publication date: January 8, 2015Applicant: Sapphire Energy, Inc.Inventors: NICOLE A HEAPS, Craig A Behnke, David Molina
-
Publication number: 20150010985Abstract: The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell.Type: ApplicationFiled: May 28, 2014Publication date: January 8, 2015Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The Board of Trustees of the University of Illinois, BP CORPORATION NORTH AMERICA INC.Inventors: N. Louise GLASS, Chaoguang TIAN, William T. BEESON, IV, Huimin ZHAO, Jing DU, Jin Ho CHOI, James H. DOUDNA CATE, Jonathan M. GALAZKA, Suk-Jin HA, Yong-Su JIN, Soo Rin KIM, Sijin LI, Xiaomin YANG
-
Publication number: 20150011482Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.Type: ApplicationFiled: March 15, 2013Publication date: January 8, 2015Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill
-
Publication number: 20150010969Abstract: The disclosure provides a method for creating a transformant having significantly improved glucaric acid-producing capability and a method for efficiently producing glucaric acid using the transformant.Type: ApplicationFiled: February 19, 2013Publication date: January 8, 2015Applicant: ASAHI KASEI CHEMICALS CORPORATIONInventors: Kazunobu Konishi, Shinichi Imazu
-
Patent number: 8927234Abstract: It is intended to provide a simple method for producing hyaluronic acid at a high yield. Further, it is also intended to provide a method for producing hyaluronic acid in a short period of time. The invention provides a method for producing hyaluronic acid including a step of culturing a microorganism having the capability to produce hyaluronic acid and a step of adding glutamine and arginine to a culture medium during late logarithmic growth phase of the microorganism.Type: GrantFiled: July 25, 2008Date of Patent: January 6, 2015Assignee: Denki Kagaku Kogyo Kabushiki KaishaInventors: Masamichi Hashimoto, Teruaki Kakema, Kenji Fujii, Masahisa Ikemi
-
Publication number: 20150004185Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: University of SaskatchewanInventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
-
Publication number: 20140378343Abstract: Stable, constitutively expressed, chromosomal fluorescent transcriptional fusions in bacterial pathogens and methods of using the same to screen candidate compounds for anti-bacterial efficacy.Type: ApplicationFiled: November 14, 2013Publication date: December 25, 2014Inventors: Daniel J. Hassett, Shengchang Su, Thomas J. Lankin, Roland Saldanha
-
Publication number: 20140377407Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.Type: ApplicationFiled: January 29, 2013Publication date: December 25, 2014Applicant: DSM IP ASSETS B.V.Inventor: Lucie Parenicova